Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4–5 chronic kidney disease

Bhamidimarri, Kalyan Ram

doi:10.21037/atm.2016.10.41

Ann. Transl. Med.

2016

DOI: 10.21037/atm.2016.10.41

|View full text |Cite

Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4–5 chronic kidney disease

Kalyan Ram Bhamidimarri

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities

et al. 2021

View full text Add to dashboard Cite

Background Chimeric antigen receptor (CAR)-modi ed T cell therapy has shown great potential in the immunotherapy of patients with hematologic malignancies. In spite of this striking achievement, there are still major challenges to overcome in CAR T cell therapy of solid tumors, including treatmentrelated toxicity and speci city. Also, other obstacles may be encountered in tackling solid tumors, such as their immunosuppressive microenvironment, the heterogeneous expression of cell surface markers, and the cumbersome arrival of T cells at the tumor site. Although several strategies have been developed to overcome these challenges, aditional research aimed at enhancing its e cacy with minimum side effects, the design of precise yet simpli ed work ows and the possibility to scale-up production with reduced costs and related risks is still warranted. Conclusions Here, we review main strategies to establish a balance between the toxicity and activity of CAR T cells in order to enhance their speci city and surpass immunosuppression. In recent years, many clinical studies have been conducted that eventually led to approved products. To date, the FDA has approved two anti-CD19 CAR T cell products for non-Hodgkin lymphoma therapy, i.e., axicbtagene ciloleucel and tisagenlecleucel. With all the advances that have been made in the eld of CAR T cell therapy for hematologic malignancies therapy, ongoing studies are focused on optimizing its e cacy and speci city, as well as reducing the side effects. Also, the efforts are poised to broaden CAR T cell therapeutics for other cancers, especially solid tumors.

show abstract

CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities

et al. 2021

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4–5 chronic kidney disease

Cited by 1 publication

References 18 publications

CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities

CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities

Contact Info

Product

Resources

About